PLP-Tesa & Ipamorelin Blend – 14mg/7mg (21mg Total)

This blend combines PLP-Tesa, a 44-amino acid GHRH analog, with Ipamorelin, a selective pentapeptide growth hormone secretagogue, in a single lyophilized vial at a 14mg/7mg ratio. The combination is designed to engage two distinct, complementary receptor pathways involved in growth hormone regulation within one research formulation.

Mechanism & Research Rationale:

PLP-Tesa is a synthetic GHRH analog featuring a trans-3-hexenoic acid modification at the N-terminus, which enhances stability and resistance to enzymatic degradation compared to endogenous GHRH, allowing it to more effectively stimulate pituitary growth hormone release through the GHRH receptor pathway. Ipamorelin, by contrast, is a selective GHRP that activates the ghrelin receptor (GHS-R1a), demonstrating unique selectivity for GH release without stimulating ACTH or cortisol. The rationale for combining them stems from research showing that GHRH analogs primarily stimulate GH synthesis and amplify GH pulse amplitude, while GHRPs modulate pulse frequency and timing by acting on distinct receptors and intracellular signaling cascades — meaning the two peptides engage separate, non-competing mechanisms simultaneously.

Key Research Areas:

• Growth Hormone Pulse Dynamics — Research models study how combined administration produces a stronger, more sustained GH secretory pulse than either compound individually, by engaging amplitude (GHRH pathway) and frequency/timing (ghrelin receptor) regulation together.
• Selective Hormone Profile — Ipamorelin’s research profile is notable for demonstrating unique selectivity for GH release without stimulating ACTH or cortisol, distinguishing it among GH secretagogues studied in this class.
• Pituitary Somatotroph Signaling — PLP-Tesa engages the GHRH receptor’s Gs-protein/adenylyl cyclase/cAMP/PKA pathway, while Ipamorelin engages the ghrelin receptor’s Gq-protein/calcium/PKC pathway — two mechanistically distinct downstream cascades converging on GH gene transcription and release.

Product Specifications:

• PLP-Tesa: 14mg | 44 amino acids | Trans-3-hexenoic acid N-terminal modification
• Ipamorelin: 7mg | Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ | 5 amino acids
• 21mg total lyophilized powder per vial
• ≥99% purity, third-party COA available (mass spectrometry recommended)
• Store refrigerated (2–8°C)

For laboratory and research use only. Not intended for human or animal consumption, diagnostic, or therapeutic use. Not a drug, dietary supplement, or cosmetic. Not FDA-approved.